Live Breaking News & Updates on Rapt therapeutics inc

Stay informed with the latest breaking news from Rapt therapeutics inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Rapt therapeutics inc and stay connected to the pulse of your community

Rapt slapped with phase II hold on CCR4 prospect

On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma.

Rapt-therapeutics-inc , Rapt-therapeutics , Rapt-therapeutics-inc- , Zelnecirnon , Rpt-193 , Atopic-dermatitis , Asthma , Clinical-hold , Bioworld , Clinical , Respiratory

Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $36.33

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month target price […]

Alger , Algeria , Canada , United-states , China , Cantor-fitzgerald , Rapt-therapeutics-inc , Therapeutics-inc , Nasdaq , Tower-research-capital , Wolfe-research

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among […]

United-states , Alger , Algeria , Canada , China , Nasdaq , Fred-alger-management , Tower-research-capital , China-universal-asset-management-co , Cantor-fitzgerald , Jpmorgan-chase-co

RAPT Therapeutics (RAPT) Announces Clinical Hold on Studies Evaluating Zelnecirnon

RAPT Therapeutics (RAPT) Announces Clinical Hold on Studies Evaluating Zelnecirnon
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Brian-wong , Drug-administration , Rapt-therapeutics-inc , Nasdaq ,

RAPT Therapeutics stock plunges as FDA halts two clinical trials

RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its...

Brian-wong , Rapt-therapeutics-inc , Drug-administration , Goldman-sachs , Article-normal , Biotechnology-services , Pharmaceuticals , Computers-consumer-electronics , Software , Applications-software , Healthcare-life-sciences , Biopharmaceuticals

Baystreet.ca - RAPT Pummeled on FDA Word

RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares descended Tuesday. The clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs ...

Nasdaq , Drug-administration , Rapt-therapeutics-inc ,

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Sells $20,456.44 in Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) insider Dirk G. Brockstedt sold 898 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $22.78, for a total transaction of $20,456.44. Following the completion of the transaction, the insider now directly owns 27,820 shares […]

Alger , Algeria , Canada , United-states , Dirkg-brockstedt , Royal-bank , Securities-exchange-commission , Exchange-traded-concepts , Jpmorgan-chase-co , Nasdaq , Therapeutics-inc

RAPT Therapeutics (NASDAQ:RAPT) Stock Price Down 5.4%

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) shares fell 5.4% during mid-day trading on Friday . The stock traded as low as $22.08 and last traded at $22.20. 5,782 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 247,016 shares. The stock had previously closed at $23.47. […]

United-states , Switzerland , Swiss , Berenberg-bank , Swiss-national-bank , Securities-exchange-commission , Dimensional-fund-advisors , Jpmorgan-chase-co , Metlife-investment-management , Nasdaq , Therapeutics-inc

RAPT Therapeutics (NASDAQ:RAPT) Shares Down 5.4%

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report)’s share price fell 5.4% on Friday . The stock traded as low as $22.08 and last traded at $22.20. 5,782 shares were traded during trading, a decline of 98% from the average session volume of 247,016 shares. The stock had previously closed at $23.47. Wall Street Analysts […]

Alger , Algeria , Canada , United-states , Royal-bank , Rapt-therapeutics-inc , Therapeutics-inc , Therapeutics-company-profile , Nasdaq , Berenberg-bank , Exchange-traded-concepts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider William Ho Sells 2,500 Shares of Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) insider William Ho sold 2,500 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $21.68, for a total transaction of $54,200.00. Following the completion of the transaction, the insider now directly owns 15,020 shares in […]

United-states , Therapeutics-company-profile , Pricet-rowe-associates-inc , Perceptive-advisors , Berenberg-bank , Therapeutics-inc , Blackrock-inc , Rapt-therapeutics-inc , Vanguard-group-inc , Nasdaq , Jpmorgan-chase-co